Apimeds Pharmaceuticals US, Inc (APUS)
Automate Your Wheel Strategy on APUS
With Tiblio's Option Bot, you can configure your own wheel strategy including APUS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol APUS
- Rev/Share 0.0
- Book/Share 0.9391
- PB 2.332
- Debt/Equity 0.0513
- CurrentRatio 12.793
- ROIC -0.352
- MktCap 27525694.0
- FreeCF/Share -0.3537
- PFCF -7.5047
- PE -6.1229
- Debt/Assets 0.0474
- DivYield 0
- ROE -2.6622
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
Published: August 25, 2025 by: Business Wire
Sentiment: Neutral
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business's STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders. Future Labs is part of Apimeds' ai² innovation platform, connectin.
Read More
About Apimeds Pharmaceuticals US, Inc (APUS)
- IPO Date 2025-05-09
- Website https://www.apimedsus.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Erik C. Emerson
- Employees 2